SeaStar Medical宣布新发布的Quelimmune健康经济学研究预测,在治疗儿科急性肾损伤方面能够显著降低医疗保健成本,这主要归因于预期的住院时间缩短和生存率提高。
SeaStar Medical宣布新发布的Quelimmune健康经济学研究预测,在治疗儿科急性肾损伤方面能够显著降低医疗保健成本,这主要归因于预期的住院时间缩短和生存率提高。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.